New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
11:20 EDTEXEL, RHHBYExelixis seen as potential target for Roche, TheStreet says
David Miller thinks Roche (RHHBY) will likely acquire Exelixis (EXEL) after the partners announced a phase III study of coBRIM in melanoma met its primary endpoint, reported TheStreet's Adam Feuerstein. Shares of Exelixis are up nearly 8% following this morning report on the trial. Reference Link
News For EXEL;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2015
17:48 EDTRHHBYPacific Biosciences launches new sequencing platform
Subscribe for More Information
September 28, 2015
10:43 EDTRHHBYRoche to hold an analyst briefing with a conference call hookup
Subscribe for More Information
07:52 EDTRHHBYIIR Holdings to hold a conference
Subscribe for More Information
05:15 EDTRHHBYGenentech announces Phase III study of ocrelizumab met primary endpoint
Subscribe for More Information
September 27, 2015
17:02 EDTRHHBYNewLink Genetics reports early Phase 1a data on GDC-0919
Subscribe for More Information
16:42 EDTRHHBYRoche present Phase 2 results on atezolizumab for urothelial cancer
Subscribe for More Information
16:40 EDTRHHBYRoche reports results from two Phase 2 studies on atezolizumab
Genentech, a member of the Roche Group, announced results from two Phase 2 studies that evaluated the investigational cancer immunotherapy atezolizumab -- or anti-PDL1; MPDL3280A -- in people with advanced non-small cell lung cancer. In the randomized Phase 2 study POPLAR, atezolizumab met its primary endpoint and showed a statistically significant survival benefit compared to chemotherapy in people with recurrent NSCLC whose tumors expressed medium and high levels of PD-L1, which corresponded with people living 7.7 months longer than people who received docetaxel chemotherapy. A separate, single-arm Phase 2 study, BIRCH, met its primary endpoint and showed that atezolizumab shrank tumors in up to 27% of people whose disease had progressed on prior medicines and also expressed the highest levels of PD-L1. Median survival had not yet been reached. In both studies of atezolizumab, adverse events were consistent with those observed in previous studies. "We plan to submit these results to global health authorities to bring this potential new option to people as soon as possible," said Chief Medical Officer Sandra Horning.
September 25, 2015
18:49 EDTEXELExelixis up 16% after Phase 3 trial of cabozantinib met primary endpoint
In after-hours trading, shares are up 16% to $6.86.
18:16 EDTEXELExelixis says Phase 3 trial of cabozantinib met primary endpoint
Exelixis announced positive results from METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with renal cell carcinoma who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor. In July 2015, Exelixis disclosed that the trial met its primary endpoint, demonstrating a statistically significant increase in progression-free survival for patients in the cabozantinib arm. Principal investigator Toni K. Choueiri, M.D. will present detailed data from the late-breaking METEOR abstract on Saturday, September 26, during the Presidential Session I at the European Cancer Congress 2015, which is being held September 25-29 in Vienna. The METEOR data and an accompanying editorial were also published today in The New England Journal of Medicine.
12:47 EDTEXELExelixis management to meet with William Blair
Meetings to be held in Europe on September 29-30 hosted by William Blair.
07:42 EDTEXEL, RHHBYExelixis: CHMP adopts positive opinion for cobimetinib, vemurafenib combination
Subscribe for More Information
07:22 EDTEXEL, RHHBYEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
06:23 EDTRHHBYRoche CEO: Will see growth regardless of setbacks, Reuters reports
Roche Holding's product lineup is so good that the company will see growth regardless of setbacks, Reuters reports, citing an interview with CEO Severn Schwan with Finanz und Wirtschaft. "Roche could have six new active pharmaceutical ingredients approved within two years. We never had this before," Schwan said. Reference Link
September 23, 2015
07:18 EDTEXELExelixis to hold a webcast
Subscribe for More Information
September 22, 2015
07:43 EDTRHHBYDrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
06:19 EDTRHHBYClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
September 21, 2015
14:28 EDTRHHBYTuring CEO says will not change Daraprim price despite criticism
Subscribe for More Information
11:24 EDTRHHBYHillary Clinton vows to take on 'outrageous' specialty drug pricing
Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug called Daraprim which treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. The presidential nominee stated in a tweet, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." The iShares Nasdaq Biotechnology Index (IBB) moved lower following Clinton's tweet.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use